These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 30377559)

  • 1. Epigenetic priming of both tumor and NK cells augments antibody-dependent cellular cytotoxicity elicited by the anti-PD-L1 antibody avelumab against multiple carcinoma cell types.
    Hicks KC; Fantini M; Donahue RN; Schwab A; Knudson KM; Tritsch SR; Jochems C; Clavijo PE; Allen CT; Hodge JW; Tsang KY; Schlom J; Gameiro SR
    Oncoimmunology; 2018; 7(11):e1466018. PubMed ID: 30377559
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Avelumab, an IgG1 anti-PD-L1 Immune Checkpoint Inhibitor, Triggers NK Cell-Mediated Cytotoxicity and Cytokine Production Against Triple Negative Breast Cancer Cells.
    Juliá EP; Amante A; Pampena MB; Mordoh J; Levy EM
    Front Immunol; 2018; 9():2140. PubMed ID: 30294328
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti-PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells.
    Boyerinas B; Jochems C; Fantini M; Heery CR; Gulley JL; Tsang KY; Schlom J
    Cancer Immunol Res; 2015 Oct; 3(10):1148-1157. PubMed ID: 26014098
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhanced killing of chordoma cells by antibody-dependent cell-mediated cytotoxicity employing the novel anti-PD-L1 antibody avelumab.
    Fujii R; Friedman ER; Richards J; Tsang KY; Heery CR; Schlom J; Hodge JW
    Oncotarget; 2016 Jun; 7(23):33498-511. PubMed ID: 27172898
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-tumor effects of NK cells and anti-PD-L1 antibody with antibody-dependent cellular cytotoxicity in PD-L1-positive cancer cell lines.
    Park JE; Kim SE; Keam B; Park HR; Kim S; Kim M; Kim TM; Doh J; Kim DW; Heo DS
    J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32830112
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analyses of the peripheral immunome following multiple administrations of avelumab, a human IgG1 anti-PD-L1 monoclonal antibody.
    Donahue RN; Lepone LM; Grenga I; Jochems C; Fantini M; Madan RA; Heery CR; Gulley JL; Schlom J
    J Immunother Cancer; 2017; 5():20. PubMed ID: 28239472
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ADCC employing an NK cell line (haNK) expressing the high affinity CD16 allele with avelumab, an anti-PD-L1 antibody.
    Jochems C; Hodge JW; Fantini M; Tsang KY; Vandeveer AJ; Gulley JL; Schlom J
    Int J Cancer; 2017 Aug; 141(3):583-593. PubMed ID: 28477372
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FcγR3A polymorphism influences natural killer cell activation and response to anti-PD-L1 (avelumab) in gestational trophoblastic neoplasia.
    Msika A; Mathias V; Boudigou M; Chambon M; Dubois V; Hajri T; Lotz JP; Massardier J; Descargues P; Gladieff L; Joly F; Lebreton C; Maucort-Boulch D; Bin S; Rousset P; Allias F; Gaillot-Durand L; Devouassoux-Shisheboran M; Lemaitre N; Alfaidy N; Langlois-Jacques C; Alves-Ferreira M; Golfier F; You B; Thaunat O; Bolze PA; Koenig A
    Am J Obstet Gynecol; 2024 Oct; ():. PubMed ID: 39370035
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunotherapy utilizing the combination of natural killer- and antibody dependent cellular cytotoxicity (ADCC)-mediating agents with poly (ADP-ribose) polymerase (PARP) inhibition.
    Fenerty KE; Padget M; Wolfson B; Gameiro SR; Su Z; Lee JH; Rabizadeh S; Soon-Shiong P; Hodge JW
    J Immunother Cancer; 2018 Nov; 6(1):133. PubMed ID: 30486888
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-PD-L1/TGFβR2 (M7824) fusion protein induces immunogenic modulation of human urothelial carcinoma cell lines, rendering them more susceptible to immune-mediated recognition and lysis.
    Grenga I; Donahue RN; Gargulak ML; Lepone LM; Roselli M; Bilusic M; Schlom J
    Urol Oncol; 2018 Mar; 36(3):93.e1-93.e11. PubMed ID: 29103968
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibody-dependent cellular cytotoxicity-inducing antibodies enhance the natural killer cell anti-cancer response against patient-derived pancreatic cancer organoids.
    Beelen NA; Aberle MR; Bruno V; Olde Damink SWM; Bos GMJ; Rensen SS; Wieten L
    Front Immunol; 2023; 14():1133796. PubMed ID: 37520563
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analyses of functions of an anti-PD-L1/TGFβR2 bispecific fusion protein (M7824).
    Jochems C; Tritsch SR; Pellom ST; Su Z; Soon-Shiong P; Wong HC; Gulley JL; Schlom J
    Oncotarget; 2017 Sep; 8(43):75217-75231. PubMed ID: 29088859
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Avelumab: combining immune checkpoint inhibition and antibody-dependent cytotoxicity.
    Hamilton G; Rath B
    Expert Opin Biol Ther; 2017 Apr; 17(4):515-523. PubMed ID: 28274143
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HDAC Inhibition Upregulates PD-1 Ligands in Melanoma and Augments Immunotherapy with PD-1 Blockade.
    Woods DM; Sodré AL; Villagra A; Sarnaik A; Sotomayor EM; Weber J
    Cancer Immunol Res; 2015 Dec; 3(12):1375-85. PubMed ID: 26297712
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exploring the potential of combining IL-2-activated NK cells with an anti-PDL1 monoclonal antibody to target multiple myeloma-associated macrophages.
    Ehlers FAI; Mahaweni NM; van de Waterweg Berends A; Saya T; Bos GMJ; Wieten L
    Cancer Immunol Immunother; 2023 Jun; 72(6):1789-1801. PubMed ID: 36656341
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of WEE1 kinase and cell cycle checkpoint activation sensitizes head and neck cancers to natural killer cell therapies.
    Friedman J; Morisada M; Sun L; Moore EC; Padget M; Hodge JW; Schlom J; Gameiro SR; Allen CT
    J Immunother Cancer; 2018 Jun; 6(1):59. PubMed ID: 29925431
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibody-dependent cell-mediated cytotoxicity using T cells with NK-like phenotype in combination with avelumab, an anti-PD-L1 antibody.
    Liu D; Hu Y; Wei J; Zhang W; Piao C; Lu Y; Wang Y; Liu J; Lu X
    Immunology; 2022 Oct; 167(2):212-220. PubMed ID: 35751879
    [TBL] [Abstract][Full Text] [Related]  

  • 18. pHLIP-fused PD-L1 engages avelumab to elicit NK cytotoxicity under acidic conditions.
    Feng J; Zheng H; Zhang Y; Wu H; Wang M; Sun Y; Zhang M; Xiao H; Qiao C; Wang J; Luo L; Li X; Feng J; Shi Y; Zheng Y; Wang Y; Sheng D; Chen G
    Heliyon; 2024 May; 10(9):e30551. PubMed ID: 38756565
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficient ADCC killing of meningioma by avelumab and a high-affinity natural killer cell line, haNK.
    Giles AJ; Hao S; Padget M; Song H; Zhang W; Lynes J; Sanchez V; Liu Y; Jung J; Cao X; Fujii R; Jensen R; Gillespie D; Schlom J; Gilbert MR; Nduom EK; Yang C; Lee JH; Soon-Shiong P; Hodge JW; Park DM
    JCI Insight; 2019 Oct; 4(20):. PubMed ID: 31536478
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Malignant Mesothelioma Effusions Are Infiltrated by CD3
    Khanna S; Thomas A; Abate-Daga D; Zhang J; Morrow B; Steinberg SM; Orlandi A; Ferroni P; Schlom J; Guadagni F; Hassan R
    J Thorac Oncol; 2016 Nov; 11(11):1993-2005. PubMed ID: 27544053
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.